featured
Oncolytic Adenoviral Therapy Plus Pembrolizumab for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Nat. Med. 2024 Jun 06;[EPub Ahead of Print], R Li, PH Shah, TF Stewart, JK Nam, TJ Bivalacqua, DL Lamm, EM Uchio, DM Geynisman, JM Jacob, JJ Meeks, R Dickstein, SM Pearce, SH Kang, SI Jung, AM Kamat, JM Burke, KA Keegan, GD SteinbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.